{"organizations": [], "uuid": "2991c5445d59b55f3c44437d8992dcac8831c963", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nymox-reports-5-yr-results-from-pr/brief-nymox-reports-5-yr-results-from-prostate-cancer-study-of-fexapotide-triflutate-in-146-u-s-men-idUSFWN1PH10X", "country": "US", "domain_rank": 408, "title": "BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T20:59:00.000+02:00", "replies_count": 0, "uuid": "2991c5445d59b55f3c44437d8992dcac8831c963"}, "author": "", "url": "https://www.reuters.com/article/brief-nymox-reports-5-yr-results-from-pr/brief-nymox-reports-5-yr-results-from-prostate-cancer-study-of-fexapotide-triflutate-in-146-u-s-men-idUSFWN1PH10X", "ord_in_thread": 0, "title": "BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men", "locations": [], "entities": {"persons": [{"name": "gleason", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "nymox pharmaceutical corp", "sentiment": "none"}, {"name": "u.s. men reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nymox pharmaceutical corp", "sentiment": "none"}, {"name": "nymox", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 22, 2018 / 7:00 PM / Updated 2 minutes ago BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men Reuters Staff 1 Min Read \nJan 22 (Reuters) - Nymox Pharmaceutical Corp: \n* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN \n* NYMOX - HIGH DOSE FEXAPOTIDE 15MG SINGLE DOSAGE TREATMENT RESULTED IN 80% LESS SURGERY OR RADIOTHERAPY ASSOCIATED WITH GLEASON GRADE PROGRESSION \n* NYMOX PHARMACEUTICAL CORP - STUDY ALSO SHOWED THAT BOTH DOSES OF FEXAPOTIDE WERE CONSISTENTLY EFFECTIVE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T20:59:00.000+02:00", "crawled": "2018-01-22T21:13:11.010+02:00", "highlightTitle": ""}